KINE SCIENCES’ technological platform starts from peptide monotherapy and evolves to peptide cocktail therapy combined with functional immunomics & AI.
We have ground-breaking works related to a novel cytokine, ERDR1(Erythroid Differentiation Regulator 1) which is a downstream of IL-18.Starting from there, we derive drug candidates for chronic immune disorders using our proprietary technology of discovering and screening “immune-modulating” small peptide molecules. Synthetic peptides comprised of less than 10 natural amino acids are hardly recognized by human immune surveillance system, which is a very attractive property of a drug candidate for chronic diseases.
Cytokines are a large group of proteins, peptides or glycoproteins that are secreted by specific cells of immune system.Cytokines are a category of signaling molecules that mediate and regulate immunity, inflammation and hematopoiesis.
ERDR1 is an anti-inflammatory cytokine downstream of IL-18.Dr. Daeho Cho, one of the founder of KINE SCIENCES discovered the function of ERDR1 for the first time in the world in 2010 and Dr. Cho’s laboratory accounts for 60% of research publication worldwide.
How we derive drug candidates from ERDR1?ERDR1, a cytokine of 177 amino acids, are broken down into each functional units, reduced the size of each unit, and then selected minimal size peptides which retain biological function.